Assertio Holdings, Inc. (ASRT)
USD 0.62
(2.78%)
USD 0.62
(2.78%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 40.91 Million USD | -38.82% |
| 2022 | 66.87 Million USD | -9.01% |
| 2021 | 73.49 Million USD | -12.61% |
| 2020 | 84.1 Million USD | -76.06% |
| 2019 | 351.25 Million USD | -37.95% |
| 2018 | 566.1 Million USD | -9.67% |
| 2017 | 626.73 Million USD | -12.81% |
| 2016 | 718.77 Million USD | -10.88% |
| 2015 | 806.5 Million USD | 250.82% |
| 2014 | 229.89 Million USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | -100.0% |
| 2010 | 2.17 Million USD | -63.33% |
| 2009 | 5.91 Million USD | -35.2% |
| 2008 | 9.13 Million USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | -100.0% |
| 2004 | 10.38 Million USD | 5.83% |
| 2003 | 9.81 Million USD | 1095.43% |
| 2002 | 820.94 Thousand USD | -86.59% |
| 2001 | 6.12 Million USD | 214.38% |
| 2000 | 1.94 Million USD | 238.85% |
| 1999 | 574.77 Thousand USD | -17.89% |
| 1998 | 700 Thousand USD | 0.0% |
| 1997 | - USD | -100.0% |
| 1996 | 300 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 40.64 Million USD | -0.29% |
| 2024 Q1 | 40.76 Million USD | -0.35% |
| 2023 Q4 | 40.91 Million USD | 5.26% |
| 2023 Q2 | 38.25 Million USD | -0.96% |
| 2023 FY | 40.91 Million USD | -38.82% |
| 2023 Q3 | 38.86 Million USD | 1.61% |
| 2023 Q1 | 38.62 Million USD | -42.25% |
| 2022 Q2 | 61.16 Million USD | -16.81% |
| 2022 Q4 | 66.87 Million USD | -1.88% |
| 2022 FY | 66.87 Million USD | -9.01% |
| 2022 Q3 | 68.15 Million USD | 11.44% |
| 2022 Q1 | 73.52 Million USD | 0.04% |
| 2021 Q3 | 78.66 Million USD | -0.39% |
| 2021 FY | 73.49 Million USD | -12.61% |
| 2021 Q4 | 73.49 Million USD | -6.58% |
| 2021 Q1 | 84.17 Million USD | 0.08% |
| 2021 Q2 | 78.97 Million USD | -6.18% |
| 2020 Q4 | 84.1 Million USD | -4.69% |
| 2020 Q1 | 57.86 Million USD | -83.53% |
| 2020 Q2 | 99.2 Million USD | 71.44% |
| 2020 Q3 | 88.24 Million USD | -11.05% |
| 2020 FY | 84.1 Million USD | -76.06% |
| 2019 Q1 | 544.02 Million USD | -3.9% |
| 2019 Q2 | 495.07 Million USD | -9.0% |
| 2019 Q4 | 351.25 Million USD | -3.92% |
| 2019 Q3 | 365.58 Million USD | -26.16% |
| 2019 FY | 351.25 Million USD | -37.95% |
| 2018 Q1 | 632.14 Million USD | 0.86% |
| 2018 FY | 566.1 Million USD | -9.67% |
| 2018 Q4 | 566.1 Million USD | -3.32% |
| 2018 Q3 | 585.52 Million USD | 0.95% |
| 2018 Q2 | 580.03 Million USD | -8.24% |
| 2017 Q2 | 629.55 Million USD | -12.98% |
| 2017 Q4 | 626.73 Million USD | -1.21% |
| 2017 FY | 626.73 Million USD | -12.81% |
| 2017 Q1 | 723.42 Million USD | 0.65% |
| 2017 Q3 | 634.38 Million USD | 0.77% |
| 2016 Q4 | 718.77 Million USD | 0.64% |
| 2016 Q3 | 714.18 Million USD | 0.63% |
| 2016 FY | 718.77 Million USD | -10.88% |
| 2016 Q1 | 804.56 Million USD | -0.24% |
| 2016 Q2 | 709.72 Million USD | -11.79% |
| 2015 Q4 | 806.5 Million USD | 0.49% |
| 2015 Q3 | 802.6 Million USD | 0.47% |
| 2015 Q2 | 798.83 Million USD | 242.76% |
| 2015 Q1 | 233.05 Million USD | 1.38% |
| 2015 FY | 806.5 Million USD | 250.82% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q4 | 229.89 Million USD | 1.38% |
| 2014 FY | 229.89 Million USD | 0.0% |
| 2014 Q3 | 226.77 Million USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2011 Q2 | 121 Thousand USD | -89.57% |
| 2011 FY | - USD | -100.0% |
| 2011 Q3 | - USD | -100.0% |
| 2011 Q1 | 1.16 Million USD | -46.54% |
| 2011 Q4 | - USD | 0.0% |
| 2010 FY | 2.17 Million USD | -63.33% |
| 2010 Q4 | 2.17 Million USD | -31.09% |
| 2010 Q2 | 4.09 Million USD | -18.33% |
| 2010 Q3 | 3.14 Million USD | -23.18% |
| 2010 Q1 | 5.01 Million USD | -15.18% |
| 2009 Q4 | 5.91 Million USD | -12.79% |
| 2009 Q1 | 8.44 Million USD | -7.53% |
| 2009 Q3 | 6.78 Million USD | -11.04% |
| 2009 Q2 | 7.62 Million USD | -9.66% |
| 2009 FY | 5.91 Million USD | -35.2% |
| 2008 Q4 | 9.13 Million USD | 0.12% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | 9.13 Million USD | 0.0% |
| 2008 Q2 | 3.51 Million USD | 0.0% |
| 2008 Q3 | 9.12 Million USD | 159.68% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q2 | 5528.00 USD | -99.95% |
| 2005 Q1 | 10.53 Million USD | 1.42% |
| 2005 FY | - USD | -100.0% |
| 2005 Q3 | - USD | -100.0% |
| 2004 FY | 10.38 Million USD | 5.83% |
| 2004 Q2 | 10.05 Million USD | 1.43% |
| 2004 Q4 | 10.38 Million USD | 1.67% |
| 2004 Q3 | 10.21 Million USD | 1.59% |
| 2004 Q1 | 9.91 Million USD | 1.02% |
| 2003 Q4 | 9.81 Million USD | 1.06% |
| 2003 Q3 | 9.71 Million USD | 1.0% |
| 2003 Q2 | 9.61 Million USD | 0.95% |
| 2003 Q1 | 9.52 Million USD | 1060.14% |
| 2003 FY | 9.81 Million USD | 1095.43% |
| 2002 Q2 | 6.99 Million USD | 0.47% |
| 2002 Q3 | 7 Million USD | 0.04% |
| 2002 Q4 | 820.94 Thousand USD | -88.27% |
| 2002 FY | 820.94 Thousand USD | -86.59% |
| 2002 Q1 | 6.96 Million USD | 13.78% |
| 2001 Q2 | 3.71 Million USD | 19.46% |
| 2001 Q3 | 5.08 Million USD | 37.03% |
| 2001 Q4 | 6.12 Million USD | 20.35% |
| 2001 FY | 6.12 Million USD | 214.38% |
| 2001 Q1 | 3.1 Million USD | 59.58% |
| 2000 Q2 | 490.78 Thousand USD | -8.0% |
| 2000 Q3 | 1.44 Million USD | 194.42% |
| 2000 Q4 | 1.94 Million USD | 34.78% |
| 2000 FY | 1.94 Million USD | 238.85% |
| 2000 Q1 | 533.45 Thousand USD | -7.19% |
| 1999 Q1 | 500 Thousand USD | -28.57% |
| 1999 Q3 | 600 Thousand USD | -14.29% |
| 1999 Q4 | 574.77 Thousand USD | -4.2% |
| 1999 FY | 574.77 Thousand USD | -17.89% |
| 1999 Q2 | 700 Thousand USD | 40.0% |
| 1998 FY | 700 Thousand USD | 0.0% |
| 1998 Q1 | 200 Thousand USD | 0.0% |
| 1998 Q2 | 200 Thousand USD | 0.0% |
| 1998 Q4 | 700 Thousand USD | 250.0% |
| 1998 Q3 | 200 Thousand USD | 0.0% |
| 1997 Q3 | 1.4 Million USD | 0.0% |
| 1997 Q4 | - USD | -100.0% |
| 1997 FY | - USD | -100.0% |
| 1996 FY | 300 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | -141.54% |
| PainReform Ltd. | 86 Thousand USD | -47472.093% |
| Alvotech | 1.07 Billion USD | 96.196% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 93.933% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | 87.026% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | 58.6% |
| Journey Medical Corporation | 17.73 Million USD | -130.75% |
| Dynavax Technologies Corporation | 256.91 Million USD | 84.076% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 92.437% |
| Bright Green Corporation | 1.85 Million USD | -2109.33% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 93.019% |
| Embecta Corp. | 1.63 Billion USD | 97.503% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -6120.418% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -6120.418% |
| SCYNEXIS, Inc. | 15.08 Million USD | -171.3% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | -394.31% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -1445.333% |
| Alpha Teknova, Inc. | 30.45 Million USD | -34.323% |
| Safety Shot Inc | 1.54 Million USD | -2541.232% |
| Procaps Group, S.A. | 285.93 Million USD | 85.692% |
| Cosmos Health Inc. | 12.42 Million USD | -229.299% |
| Theratechnologies Inc. | 58.96 Million USD | 30.62% |
| Harrow Health, Inc. | 190.5 Million USD | 78.524% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -6628.947% |
| Biofrontera Inc. | 5.39 Million USD | -657.77% |
| DURECT Corporation | 20.74 Million USD | -97.204% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 1.481% |
| Cronos Group Inc. | 2.53 Million USD | -1510.748% |
| OptiNose, Inc. | 131.74 Million USD | 68.947% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 94.282% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -12.634% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -3387.791% |
| Organogenesis Holdings Inc. | 119.35 Million USD | 65.721% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | -122.004% |
| Radius Health, Inc. | 365.31 Million USD | 88.801% |
| Universe Pharmaceuticals INC | 5.48 Million USD | -646.235% |
| ProPhase Labs, Inc. | 21.38 Million USD | -91.356% |
| Phibro Animal Health Corporation | 525.45 Million USD | 92.214% |
| Procaps Group S.A. | 285.93 Million USD | 85.692% |
| TherapeuticsMD, Inc. | 8 Million USD | -411.081% |
| Viatris Inc. | 18.12 Billion USD | 99.774% |
| Rockwell Medical, Inc. | 13.43 Million USD | -204.427% |
| Aytu BioPharma, Inc. | 15.12 Million USD | -170.421% |
| SIGA Technologies, Inc. | 1.46 Million USD | -2694.518% |
| Tilray Brands, Inc. | 387.31 Million USD | 89.437% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | 68.616% |
| Shineco, Inc. | 29.65 Million USD | -37.953% |
| PetIQ, Inc. | 468.3 Million USD | 91.264% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -68306.708% |
| Incannex Healthcare Limited | 373 Thousand USD | -10868.365% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 90.45% |
| Alimera Sciences, Inc. | 67.39 Million USD | 39.299% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -3661.352% |
| Clever Leaves Holdings Inc. | 2.08 Million USD | -1860.326% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -3860.063% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | -15.623% |
| Hempacco Co., Inc. | 13.72 Million USD | -198.095% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.07 Billion USD | 96.196% |
| Eagle Pharmaceuticals, Inc. | 62.46 Million USD | 34.505% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 93.369% |
| Currenc Group, Inc. | 31.94 Million USD | -28.076% |
| Kamada Ltd. | 8.74 Million USD | -367.62% |
| Indivior PLC | 281.6 Million USD | 85.472% |
| Evoke Pharma, Inc. | 5 Million USD | -718.24% |
| Flora Growth Corp. | 3.67 Million USD | -1014.161% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -3860.063% |
| Evolus, Inc. | 126.54 Million USD | 67.67% |
| HUTCHMED (China) Limited | 86.13 Million USD | 52.5% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 93.44% |
| Akanda Corp. | 3.99 Million USD | -923.109% |